Cargando…
Ozanimod (RPC1063), a selective S1P(R1) and S1P(R5) modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1P(R1)) and receptor 5 (S1P(R5)), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. Ozanimod and its active metabolite, RP-101...
Autores principales: | Taylor Meadows, Kristen R., Steinberg, Marcos W., Clemons, Bryan, Stokes, Matthew E., Opiteck, Gregory J., Peach, Robert, Scott, Fiona L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880347/ https://www.ncbi.nlm.nih.gov/pubmed/29608575 http://dx.doi.org/10.1371/journal.pone.0193236 |
Ejemplares similares
-
R 1063 MD - 12th October 1979, Clearing Current Study
por: Fischer, C, et al.
Publicado: (1979) -
Ozanimod for multiple sclerosis
Publicado: (2021) -
Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017) -
Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022) -
"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)